Crossmark

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

Crossref DOI link: https://doi.org/10.1038/bmt.2015.307

Published Online: 2016-01-04

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cornell, R F

Kassim, A A
License Information

Text and Data Mining valid from 2016-01-04
More Information

Article History

Received: 7 June 2015

Revised: 8 October 2015

Accepted: 22 October 2015

First Online: 4 January 2016

Competing interests

: RFC declares no potential conflicts of interest. AAK has received research grants from Novartis Pharmaceuticals and Celgene, whose products are discussed in this article.